

Boston Pharma Strategic License Arrangement with GlaxoSmithKline

Client News

March 19, 2021

Gunderson Dettmer represented client Boston Pharma, a clinical stage biopharmaceutical company developing differentiated therapeutics, in its strategic license arrangement with GSK.

In the [announcement](#), Boston Pharma CEO Robert Armstrong, Ph.D., said “We have high hopes we will have a successful outcome in the clinic that would be so compelling that GSK would be interested in pursuing the [repurchase] option.”

The Gunderson team was led by Tim Ehrlich, Peter Schoch and Joel Diamond.

Related People



Timothy H. Ehrlich

PARTNER

P +1 617 648 9399



Joel T. Diamond
ASSOCIATE
P +1 617 648 9136

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act